[go: up one dir, main page]

MX2019003105A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2019003105A
MX2019003105A MX2019003105A MX2019003105A MX2019003105A MX 2019003105 A MX2019003105 A MX 2019003105A MX 2019003105 A MX2019003105 A MX 2019003105A MX 2019003105 A MX2019003105 A MX 2019003105A MX 2019003105 A MX2019003105 A MX 2019003105A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
indacaterol
component
hfa
difluoroethane
Prior art date
Application number
MX2019003105A
Other languages
English (en)
Other versions
MX387725B (es
Inventor
James Noakes Timothy
Corr Stuart
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1615910.5A external-priority patent/GB2554089A/en
Priority claimed from GBGB1620516.3A external-priority patent/GB201620516D0/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2019003105A publication Critical patent/MX2019003105A/es
Publication of MX387725B publication Critical patent/MX387725B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se describe una composición farmacéutica. La composición comprende: (i) un componente de fármaco que comprende al menos un compuesto de indacaterol seleccionado de indacaterol y los derivados aceptables desde el punto de vista farmacéutico de este; y (ii) un componente propulsor que comprende 1,1-difluoroetano (HFA-152a).
MX2019003105A 2016-09-19 2017-09-18 Composición farmacéutica. MX387725B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1615910.5A GB2554089A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
GBGB1620516.3A GB201620516D0 (en) 2016-12-02 2016-12-02 Pharmaceutical composition
PCT/GB2017/052757 WO2018051128A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2019003105A true MX2019003105A (es) 2019-08-01
MX387725B MX387725B (es) 2025-03-18

Family

ID=59997385

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003105A MX387725B (es) 2016-09-19 2017-09-18 Composición farmacéutica.
MX2021010022A MX2021010022A (es) 2016-09-19 2019-03-15 Composicion farmaceutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010022A MX2021010022A (es) 2016-09-19 2019-03-15 Composicion farmaceutica.

Country Status (9)

Country Link
US (2) US11260052B2 (es)
EP (2) EP3515441B1 (es)
JP (2) JP6781830B2 (es)
CN (3) CN113288869A (es)
AU (2) AU2017328905C1 (es)
CA (1) CA3037080C (es)
ES (2) ES2949975T3 (es)
MX (2) MX387725B (es)
WO (1) WO2018051128A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069417A (zh) * 2016-09-19 2021-07-06 墨西哥氟石股份公司 药物组合物
US11260052B2 (en) * 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
EP4221707A4 (en) * 2020-09-29 2024-08-28 Aerorx Therapeutics LLC Liquid formulations of indacaterol
CN117679423A (zh) 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物
WO2025151671A1 (en) * 2024-01-12 2025-07-17 Texas Tech University System Compositions and methods for treating diet-induced obesity and associated metabolic disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
KR100589926B1 (ko) 1997-09-29 2006-06-15 넥타르 테라퓨틱스 천공된 미립자 및 사용 방법
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DE60019167T2 (de) 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
CA2496699C (en) 2002-08-29 2012-07-17 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
CA2510043A1 (en) 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
ES2259915B1 (es) 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2749280A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and formoterol
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
CN103857338B (zh) 2011-10-20 2017-10-31 皇家飞利浦有限公司 用于监测设备的运动与定向的设备和方法
JP2016503390A (ja) 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
US11260052B2 (en) * 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica

Also Published As

Publication number Publication date
MX2021010022A (es) 2021-09-14
US20220133709A1 (en) 2022-05-05
ES2949975T3 (es) 2023-10-04
EP3515441B1 (en) 2021-09-08
JP2020200333A (ja) 2020-12-17
CA3037080A1 (en) 2018-03-22
MX387725B (es) 2025-03-18
JP2019529430A (ja) 2019-10-17
US20190374532A1 (en) 2019-12-12
CA3037080C (en) 2021-05-18
BR112019005080A2 (pt) 2019-06-04
WO2018051128A1 (en) 2018-03-22
US11260052B2 (en) 2022-03-01
AU2020202580A1 (en) 2020-05-07
JP6781830B2 (ja) 2020-11-04
JP6972256B2 (ja) 2021-11-24
AU2020202580B2 (en) 2021-02-18
AU2017328905B2 (en) 2020-04-09
CN113288869A (zh) 2021-08-24
CN116270640A (zh) 2023-06-23
ES2891579T3 (es) 2022-01-28
AU2017328905C1 (en) 2020-08-06
EP3909582B1 (en) 2023-05-24
AU2017328905A1 (en) 2019-04-04
CN109715160A (zh) 2019-05-03
EP3909582A1 (en) 2021-11-17
EP3515441A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
MX2019003099A (es) Composicion farmaceutica.
MX2019003105A (es) Composicion farmaceutica.
CO2019002556A2 (es) Composición farmacéutica
MX2019003097A (es) Composicion farmaceutica.
CO2019002555A2 (es) Composición farmacéutica
MX2018006800A (es) Composicion farmaceutica.
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
MX2020011868A (es) Inhibidores de los receptores erbb.
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
ZA202006535B (en) Pharmaceutical composition comprising salbutamol
MX2018006799A (es) Composicion farmaceutica.
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CO2022006965A2 (es) Inhibidores de egfr
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
EA201990506A1 (ru) Фармацевтическая композиция
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
CL2018000359A1 (es) Fenoxiacetamidas apareadas novedosas
CL2018000310A1 (es) Benzamidas apareadas novedosas